Man Group
IMRX icon

Man Group’s Immuneering IMRX Stock Holding History

Man Group’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-13,914
Closed -$30.6K – 2272
2024
Q4 		$30.6K Buy
13,914
+136
+1% +$282 ﹤0.01% 1953
2024
Q3 		$34.3K Buy
+13,778
New +$20K ﹤0.01% 1929
2023
Q1 		– Sell
-18,368
Closed -$104K – 1938
2022
Q4 		$89.1K Buy
+18,368
New +$163K ﹤0.01% 1924

Other funds holding IMRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SM
Southport Management Wilson, Wyoming $28.6M AUM 41.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Man Group's IMRX Position: Q1 2025 in Review

Man Group sold out of Immuneering (IMRX) in Q1 2025, closing a stake of 13,914 shares — an estimated $30.6K sold.

Man Group first reported a position in IMRX in Q4 2022 and held it in 3 quarters. The position peaked at $89.1K in Q4 2022. 35 funds tracked by Wall St. Rank hold IMRX as of Q1 2025.

  • Man Group reported no remaining Immuneering position as of Q1 2025 after selling out during the quarter.
  • Man Group sold 13,914 Immuneering shares in Q1 2025, an estimated $30.6K.
  • Man Group first reported a position in Immuneering in Q4 2022 and held it in 3 quarters.
  • Man Group's Immuneering position peaked at $89.1K in Q4 2022.
  • 35 funds tracked by Wall St. Rank held Immuneering as of Q1 2025.

Based on Man Group's 13F filing for Q1 2025, filed 15 May 2025.